Pacira Pharmaceuticals, Inc., makers of EXPAREL®, own the proven product delivery technology, DepoFoam. DepoFoam has been used safely in two other products, and has a demonstrated safety record and history of regulatory approvals in the United States, Europe, and several other countries around the world.
How it works
The DepoFoam carrier matrix is made up of microscopic, polyhedral particles composed of numerous, non-concentric, internal aqueous chambers that encapsulate drugs without altering their molecular structure and then release them over a desired period of time. Each chamber is separated from adjacent chambers by lipid membranes. Following injection, the DepoFoam particles release medication over time due to erosion and/or reorganization of the lipid membranes.
DepoFoam-based drugs are formulated as ready-to-use, aqueous suspensions allowing for simple injection through needles with a bore size as narrow as 25 gauge.
Cutting-edge technology sets EXPAREL apart
With a unique drug delivery system, EXPAREL is designed to extend postsurgical analgesia
- Indicated for single-dose administration into the surgical site to produce postsurgical analgesia
- DepoFoam uniquely delivers bupivacaine over time to extend pharmacologic effect
- Encapsulates bupivacaine via a multivesicular liposomal drug delivery technology1
- Releases bupivacaine over time as lipid membranes reorganize1
Reliable release of a low dose of bupivacaine over time2
- Longer duration provides coverage when postsurgical pain is at its worst
- Eliminates the need for titration with a single dose
- Eliminates the need for external devices to prolong analgesia
- EXPAREL dosing is not weight based
- Different formulations of bupivacaine are not bioequivalent even if the milligram dosage is the same; therefore, it is not possible to convert dosing from any other formulation of bupivacaine to EXPAREL and vice versa
- Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL